Workflow
成人健康细胞存储
icon
Search documents
中源协和: 中源协和细胞基因工程股份有限公司关于收购子公司上海中源济生细胞科技有限公司股东所持部分股权暨关联交易的公告
Zheng Quan Zhi Xing· 2025-07-29 16:33
Core Viewpoint - The company plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. to enhance operational decision-making efficiency and increase resource investment in the adult health cell storage business, with the transaction price set at RMB 3,819,575 based on an asset appraisal value of RMB 1,527.83 million [1][9][15]. Transaction Overview - The transaction involves the acquisition of a 25% equity stake in Shanghai Zhongyuan Jisheng Company, which is a subsidiary of the company, with a total investment of RMB 5,250 million, where the company holds a 75% stake [2][7]. - The transaction is classified as a related party transaction due to the seller being controlled by the company's actual controller, Chen Chunmei [2][5]. - The transaction does not constitute a major asset restructuring and does not require approval from the company's shareholders' meeting [2][15]. Financial Information - The appraisal report indicates that the total equity value of Shanghai Zhongyuan Jisheng Company is RMB 1,527.83 million, with a valuation increase of 18.72% compared to the book value [9][11]. - The financial performance of Shanghai Zhongyuan Jisheng Company shows total assets of RMB 69.21 million and total liabilities of RMB 56.34 million as of December 31, 2024, with a net profit of -24.06 million [8]. Payment Arrangement - The payment for the equity transfer will be made in two installments: 50% within 5 days of the agreement's effectiveness and the remaining 50% within 5 days after the completion of tax and business registration changes [4][13]. Impact on the Company - The acquisition will make Shanghai Zhongyuan Jisheng Company a wholly-owned subsidiary, which is expected to improve operational decision-making efficiency and leverage existing resources to enhance the adult health cell storage business in the East China region [14][15]. - The transaction is anticipated to create a complete business loop for the adult health cell storage market, which has significant growth potential [14][15].